NCT05672875 is a clinical trial of Anthrax LF Dx System in Anthrax, sponsored by SRI International.

Who is sponsoring NCT05672875?

NCT05672875 is sponsored by SRI International.

What drugs are being tested in NCT05672875?

Interventions in NCT05672875: Anthrax LF Dx System.

Is NCT05672875 still recruiting?

NCT05672875 is currently terminated. Last updated 30 November 2023.

Last reviewed 2023-11-30 · How we verify

NCT05672875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System

Terminated Last updated 30 November 2023

What this trial tests

trial testing Anthrax LF Dx System in Anthrax in 343 participants. Terminated before completion.

Timeline

23 January 2023

Primary endpoint
20 April 2023

20 April 2023

Quick facts

Lead sponsor	SRI International
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	343
Start date	23 January 2023
Primary completion	20 April 2023
Estimated completion	20 April 2023
Sites	3 locations across United States

Drugs / interventions tested

Anthrax LF Dx System

Conditions studied

Anthrax — all drugs for Anthrax →

Sponsor

SRI International — full company profile →

Who can join

18 and older, any sex, with Anthrax. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is intended to estimate the Anthrax LF Dx System specificity. Sensitivity will be estimated with 10% of the samples spiked with recombinant Bacillus anthracis lethal factor (LF) used to prepare contrived positive samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anthrax

Currently open trials in the same condition.

NCT06365073 — A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax · recruiting
NCT00050310 — Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of A · recruiting

Other SRI International trials

Trials by the same sponsor.

NCT05628961 — Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics · Phase 1 · completed
NCT04979507 — Sleep and Emotional Reactivity in Alcohol Use Disorder · NA · unknown
NCT03727906 — Sleep and Cardiovascular Health in Adolescence · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05672875 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SRI International
Last refreshed: 30 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing